At least 20 million Americans ages 40 and older have age-related macular degeneration, and the threat posed by the vision-robbing condition will only grow larger as the population ages. Despite the ...

Please provide your email address to receive an email when new articles are posted on . Continuous growth of macular neovascularization size, as well as development of outer retina atrophy, was ...

SEATTLE — In this Healio Video Perspective from the ARVO meeting, Jennifer I. Lim, MD, discusses anti-VEGF therapy for the treatment of proliferative sickle cell retinopathy. Lim and colleagues with ...

SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals ...

Researchers led by a team at the Wilmer Eye Institute, Johns Hopkins Medicine, have discovered why vision in some patients with neovascular (nv) or “wet” age-related macular degeneration (nvAMD, or ...

Although corticosteroids were found to immediately improve best-corrected visual acuity and central macular thickness, anti–vascular endothelial growth factor (anti-VEGF) therapies had significant ...

Early response to treatment with anti–vascular endothelial growth factor (VEGF) agents may predict long-term outcomes among patients with diabetic macular edema (DME), a small study suggests. "Our ...

A new mRNA vaccine developed in Japan has been shown to suppress abnormal blood vessel growth in the retina of mice, offering ...

Continuing anti-vascular endothelial growth factor (VEGF) therapy plus chemotherapy in the second-line setting led to a small but nonsignificant increase in overall survival in patients with ...